Ling-Qiang Zhu

Prof. Dr. Ling-Qiang Zhu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
WBWen-Dai Bao
Wen-Dai Bao
PPPei Pang
Pei Pang
XZXiao-Ting Zhou
Xiao-Ting Zhou
FHFan Hu
Fan Hu
WXWan Xiong
Wan Xiong
LZLing-Qiang Zhu
Ling-Qiang Zhu
Iron homeostasis disturbance has been implicated in Alzheimer’s disease (AD), and excess iron exacerbates oxidative damage and cognitive defects. Ferroptosis is a nonapoptotic form of cell death dependent upon intracellular iron. However, the involvement of ferroptosis in the pathogenesis of AD remains elusive. Here, we report that ferroportin1 (Fpn), the only identified mammalian nonheme iron exporter, was downregulated in the brains of APPswe/PS1dE9 mice as an Alzheimer’s mouse model and Alzheimer’s patients. Genetic deletion of Fpn in principal neurons of the neocortex and hippocampus by breeding Fpnfl/fl mice with NEX-Cre mice led to AD-like hippocampal atrophy and memory deficits. Interestingly, the canonical morphological and molecular characteristics of ferroptosis were observed in both Fpnfl/fl/NEXcre and AD mice. Gene set enrichment analysis (GSEA) of ferroptosis-related RNA-seq data showed that the differentially expressed genes were highly enriched in gene sets associated with AD. Furthermore, administration of specific inhibitors of ferroptosis effectively reduced the neuronal death and memory impairments induced by Aβ aggregation in vitro and in vivo. In addition, restoring Fpn ameliorated ferroptosis and memory impairment in APPswe/PS1dE9 mice. Our study demonstrates the critical role of Fpn and ferroptosis in the progression of AD, thus provides promising therapeutic approaches for this disease.

19 May 2012 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JWJing Wu
Jing Wu
HXHaifan Xiao
Haifan Xiao
HSHongjuan Sun
Hongjuan Sun
LZLi Zou
Li Zou
LZLing-Qiang Zhu
Ling-Qiang Zhu

7 November 2007 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LZLing-Qiang Zhu
Ling-Qiang Zhu
SWShao-Hui Wang
Shao-Hui Wang
DLDan Liu
Dan Liu
YYYang-Yang Yin
Yang-Yang Yin
QTQing Tian
Qing Tian
JWJianzhi Wang
Jianzhi Wang
Activation of glycogen synthase kinase-3 (GSK-3) can cause memory deficits as seen in Alzheimer's disease, the most common age-associated dementia, but the mechanism is not understood. Here, we found that activation of GSK-3 by wortmannin or transient overexpression of wild-type GSK-3β could suppress the induction of long-term potentiation (LTP) in rat hippocampus, whereas simultaneous inhibition of GSK-3 by lithium or SB216763 or transient expression of a dominant-negative GSK-3β mutant (dnGSK-3β) preserved the LTP. After high-frequency stimulation (HFS), the presynaptic release of glutamate and the expression/clustering of synapsin I, a synaptic vesicle protein playing an important role in neurotransmitter release, decreased markedly after upregulation of GSK-3.In vitrostudies further demonstrated that GSK-3 inhibited the expression of SynI independent of HFS. In postsynaptic level, the expression of PSD93 and NR2A/B proteins decreased significantly when GSK-3 was activated. The LTP-associated synapse impairments including less presynaptic active zone, thinner postsynaptic density, and broader synaptic cleft were also prominent in the hippocampal slices after HFS with activation of GSK-3. These synaptic impairments were attenuated when GSK-3 was simultaneously inhibited by LiCl or SB216763 or transient expression of dnGSK-3. We conclude that upregulation of GSK-3 impairs the synaptic plasticity both functionally and structurally, which may underlie the GSK-3-involved memory deficits.

1 March 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
XWXiong Wang
Xiong Wang
DLDan Liu
Dan Liu
HHHe-Zhou Huang
He-Zhou Huang
ZWZhi-Hao Wang
Zhi-Hao Wang
THTong-Yao Hou
Tong-Yao Hou
LZLing-Qiang Zhu
Ling-Qiang Zhu

1 February 2012 in Neuron
Verified
Journal Article
Closed access
YYYing Yang
Ying Yang
XSXiaogang Shu
Xiaogang Shu
DLDan Liu
Dan Liu
YSYou Shang
You Shang
YWYan Wu
Yan Wu
YLYouming Lu
Youming Lu

17 October 2020 in Aging Cell
Verified
Journal Article
Open access
PDF file
WBWen‐Dai Bao
Wen‐Dai Bao
XZXiao‐Ting Zhou
Xiao‐Ting Zhou
LZLan‐Ting Zhou
Lan‐Ting Zhou
FWFudi Wang
Fudi Wang
XYXiaoping Yin
Xiaoping Yin
DLDan Liu
Dan Liu
Incidence of intracerebral hemorrhage (ICH) and brain iron accumulation increases with age. Excess iron accumulation in brain tissues post‐ICH induces oxidative stress and neuronal damage. However, the mechanisms underlying iron deregulation in ICH, especially in the aged ICH model have not been well elucidated. Ferroportin1 (Fpn) is the only identified nonheme iron exporter in mammals to date. In our study, we reported that Fpn was significantly upregulated in perihematomal brain tissues of both aged ICH patients and mouse model. Fpn deficiency induced by injecting an adeno‐associated virus (AAV) overexpressing cre recombinase into aged Fpn‐floxed mice significantly worsened the symptoms post‐ICH, including hematoma volume, cell apoptosis, iron accumulation, and neurologic dysfunction. Meanwhile, aged mice pretreated with a virus overexpressing Fpn showed significant improvement of these symptoms. Additionally, based on prediction of website tools, expression level of potential miRNAs in ICH tissues and results of luciferase reporter assays, miR‐124 was identified to regulate Fpn expression post‐ICH. Higher serum miR‐124 levels were correlated with poor neurologic scores of aged ICH patients. Administration of miR‐124 antagomir enhanced Fpn expression and attenuated iron accumulation in aged mice model. Both apoptosis and ferroptosis, but not necroptosis, were regulated by miR‐124/Fpn signaling manipulation. Our study demonstrated the critical role of miR‐124/Fpn signaling in iron metabolism and neuronal death post‐ICH in aged murine model. Thus, Fpn upregulation or miR‐124 inhibition might be promising therapeutic approachs for this disease.